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Abstract

BIOCHEMICAL ACTIONS OF A NOVEL CIS-TERPENONE
By Lin Zhang, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Director: Qibing Zhou, Ph.D
Assistant Professor Department of Chemistry
Quinone methides are reactive species due to their electrophilicity, and natural
quinone methide analogs have broad biological activities. Based on known actions of
cytochrome P450 enzymes, we hypothesized that trans-terpenones can be metabolized in
cells to form a cascade of metabolite products, which may be biologically active due to
the generation of quinine and quinone methide reactive intermediates. Therefore, 3hydroxy-cis-terpenone (HCT) and analogs were designed and synthesized in our lab to
investigate this hypothesis.

As a first step in testing this hypothesis, we examined effects of cis-terpenones on
the viability of HepG2 cells exposed to aflatoxin B1 (AFB1). Cis-terpenones combined

xiii
with AFB1 in HepG2 cells increased cell viability suggesting chemopreventive effects
against AFB1. Further study revealed a mechanism for this effect: HCT and oxidized
HCT (OHCT) inhibited activity of P450 1A/B, which metabolizes AFB1 to toxic
metabolites, and thereby protected cells against AFB1 induced cytotoxicity.

Additional studies demonstrated that HCT inhibits accumulation of tritiumlabeled AFB1 in HepG2 cells. To investigate the mechanism of this effect we first
determined whether specific transporters affect the accumulation of AFB1 in HepG2
cells. Effects on AFB1 accumulation by pH, selected ions, inhibitors or competitive
substrates of organic cation transporters (OCT), organic anion transporters (OAT/OATP),
and multi-drug-resistant efflux transporters eliminated effects of major groups of these
transporters on AFB1 accumulation. The data indicated one or more unidentified proton
dependent transport mechanism(s) modulate cellular accumulation of AFB1 and further
demonstrated HCT inhibits accumulation of AFB1 in cells by decreasing AFB1 binding
to intracellular proteins.

Based on its potential chemoprotective actions, other biological actions of HCT
were screened. Based on evidence that terpenes modulate immune cell production of
cytokines, we examined effects of HCT on production of interleukin-6 (IL-6) and tumor
necrosis factor-α (TNFα) by cultured macrophages. HCT reduced lipopolysaccharidestimulated release of IL-6 and TNFα. MES-SA/DX5 cells that over-express the efflux
transporter MDR1 were used to examine effects of OHCT on accumulation of the MDR1
substrate estrone-sulfate and to verify that MDR1 does not transport unconjugated AFB1.

xiv
OHCT at a high concentration (120 µM) reduced cellular accumulation of estrone sulfate
suggesting enhanced MDR1-mediated efflux

1

Chapter 1
Introduction

1.1 Natural terpenes

Approximately 25,000 natural terpenes have been reported,1 however, most of
these compounds exhibit no apparent functional actions in growth and development and
were treated initially as metabolite waste. This traditional view remained until the 1970s,
and very few of these compounds were fully investigated. Starting in the 1970s, many
terpenes were discovered to have antibacterial and antifungal activity, which led to
numerous studies on these natural products.2

Many animals, plants and insects can produce terpenes and use them mostly as
defense weapons. For example, Milkweed Asclepias curassavica contains cardenolides in
its latex canals, which are toxic to insects. When Trichoplusia ni were fed onMilkweed
Asclepias curassavica, they suffered severe spasms and became immobilized (Scheme
1.1).3 Another example is termites which can produce the monoterpene-, sesquiterpeneand diterpene mixture, which the insects use as protective substances.4

2

O
O

OH

O
OH
O
OH

O

O

Scheme 1.1Structure of Calotropin, a cardenolide (J. Gershenzon, et. al,,2007)

1.2 Quinone methides

Among approximate 25,000 of terpene family members, triterpene quinone
methides (TPQMs) have attracted our attention particularly because of their quinone
methide moiety. In 1907, K. Fries first suggested a quinone methide intermediate,5 and in
1963 Gardner identified the intermediate by the pyrolysis of o-methoxymethylphenol
using spectroscopical methods (Scheme 1.2).6

Scheme 1.2 Formation of Quinone Methide (Gardner et. al., 1963)

Quinone methides are very reactive species due to their electrophilicity.
Nucleophiles can attack the methylene group and form an aromatic phenol (Scheme 1.3).

3

Scheme 1.3 Quinone Methide nucleophilic addition (V. D. Water, et. al., 2002)

Quinone methides are the intermediates that often exist in nature. Natural quinone
methide analogs can be therapeutic agents or antibiotic agents. For example, both
Vitamin E’s therapeutic effects and anthracycline’s antibiotic actionare due to formation
of quinone methide species (Scheme 1.4).7
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Scheme 1.4 Structure of Vitamin E (Van De Water, et. al., 2002)

A second exampleof quinone methideis the potent natural terpene product
Celastrol (Scheme 1.5) that is extracted from the root bark of “Thunder of God Vine”,
which has been used as traditional Chinese medicine for thousands of years to treat
inflammatory conditions.8 It has been reported that Celastrol can induce leukemia cell
apoptosis and inhibit the chymotrypsin-like activity ofa purified 20S proteasome (IC50 =

4
2.5 µmol/L) and humanprostate cancer cellular 26S proteasome (at 1-5 µmol/L). The
celastrol treatment of nude mice with PC-3 tumor resulted in great inhibition (65-93 %)
of tumor growth by inhibition of proteasome activity, which implied that Celastrol may
be used as potential antitumor drug.

Scheme1.5Structure of Celastrol, a potential chemopreventional compound
(Yang, H. J., et. al., 2006)

Another exampleof quinone methide is Tingenone (#1, Scheme 1.6),which is a
triterpene quinone methidethatexhibits 50% inhibition of growth at concentrations of 2.55 µg/mL against the P-388 lymphoid neoplasm, the A-549 human lung cancer, HT-29
colon carcinoma, and MEL-28 human melanoma cell lines.9 Celephanol(#2)can inhibit
the production of NF-κB and nitric oxide at 18 and 32 µM, respectively.10 Coleon U (#3)
exhibits 50% inhibition of cell growth at 3-6 µM against the MCF-7 breast
adenocarcinoma, NCI-H460 non-small cell lung cancer, SF-269 CNS cancer, TK-10
renal cancer, and UACC-62 melanoma.11 Coleon U quinone (#4) and its epoxide

5
derivative (#5) inhibit cell growth by 50% at concentrations of 3 and 14 µg/mL against
leukemia cells, respectively.12

Scheme 1.6Examples of bioactive natural terpene products (oxidation states increasing
from that of tingenone 1 to epoxide 5)

1.3 Target compound and analogs

By carefully examining above (compound 1-5) structures, if ignoring the different
substitution groups, Dr. Zhou and Miguel Zuniga found thatterpenes can be chemically
oxidized from one parent compound by simple oxidation and addition of a hydroxyl
group to form a cascade of analogs from Tingenone to Coleon U quinone epoxide
derivative. In our previous papers, it was demonstrated that this conversion from

6
compound (#6) to compound (#7-10) is possible in solution with the presence of Cu2+ and
HSCH2CH2OH.13-14
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Scheme 1.7 The oxidative conversion of a cascade of analogs with Cu2+ and
HSCH2CH2OH

Scheme 1.8Metabolic pathways for Trans-terpenone. (Q. Zhou, unpublished)
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8
Based on the well known actions of cytochrome P450 enzymes, Dr. Zhou
hypothesized that the trans-isomers can be metabolized in cells to form a cascade of
metabolite products (Scheme 1.8). It may be first hydrolyzed to a mixture of two catechol
isomers 11 and 12 via CYP 450. Compound 11 shown above may be oxidized to a
cascade of bioactive metabolite compounds (13-18). These compounds were
hypothesized to be potentially cytotoxic due to the generation of quinine and quinone
methide reactive intermediates, as well as reactive oxygen species.

Scheme 1.9 Structure of cis-terpenone (HCT) analogs

Based on these findings, 3-hydroxy-cis-terpenone (HCT) and analogs (Scheme
1.9) were designed and synthesized in our lab.13Based on the metabolism of estradiol, Dr.
Zhou predicted that the cis-terpenones would be hydroxylated and oxidized in liver cells.
Because the predicted metabolite partially resembles resveratrol, a compound known to
inhibit cytochrome P450 1A/B activity, we predicted that HCT also would inhibit one or
more CYP450 enzymes.

9
Although the structure of HCT is similar to that of estradiol, it has a cis
conformation which is different from related structures, such as our previous compound 6
and estradiol. We proposed that its unique bent conformation (Figure 1.1) would prevent
the formation of HCT-DNA adducts; therefore, we expected that this compound would
have no significant carcinogenic activity and may have great potential to be
chemoprevention agent.15

HCT

Estradiol

Figure 1.1The unique 3-D conformation of HCT versus that of estradiol. The bent shape
of HCT is hypothesized to prevent potential carcinogenic activity. (Q. Zhou,
unpublished)
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Chapter 2
Aflatoxins and CYP 450

2.1 Aflatoxins

Aflatoxins probably are among the most known and researched mycotoxins.These
toxins are responsible for up to 25 % of the world’s crop damage.16 They were first
detected and identified in 1960 as the cause of “Turkey X disease”.17,18 Since then,
aflatoxins have been studied worldwide because of their cytotoxicity to human liver cells
and, more importantly, because of the possibility ofcausing hepatocellular
carcinoma.Aflatoxins are secondary metabolites produced by a fungus
Aspergillusflavusand are usually found in contaminated crops such as corn, peanut and
cottonseed, as well as milk. There are four major aflatoxins: Aflatoxin B1/2 and G1/2,
plus two additional hydroxylated metabolic products,M1 and M2 (Scheme 2.1),which
were first discovered in the milk of diary cows fed with aflatoxin contaminated diet.
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Scheme 2.1 Structures of Aflatoxins

Among Aflatoxin family members, Aflatoxin B1 (AFB1) is the most toxic one. In
1988, it was listed as a human carcinogen by the International Agency for Research on
Cancer (IARC, part of the World Health Organization), based on studies in Africa and
Asia showing a positive association between AFB1 and liver cell cancer.19 The biological
metabolism of AFB1 is already well established. Bioactivation of AFB1 goes through
metabolic activation by cytochrome P450 (CYP450) to two metabolic products: AFB1
exo-8,9-epoxide and endo-8,9-epoxide. AFB1 exo-8,9-epoxide then reacts with DNA to
form a covalent bonding molecular complex that causes DNA damage.20-23 (Scheme 2.2)
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Scheme 2.2 Metabolism of AFB1 by CYP450 and bonding with DNA

In humans, P450 1A2 and 3A4 activity account for most of the enzymatic
metabolism of AFB1. Although P450 1A2 is a more efficient catalyst,24 P450 3A4
appears to be the dominant P450 involved in the formation of the exo-epoxide, due to a
larger amount of 3A4 in human liver cells compared to 1A2. P450 1A2 can oxidize
AFB1 to AFM1, AFQ1, as well as the endo- and exo-epoxide, while P450 3A4 oxidizes
AFB1 to AFQ1 and the exo-epoxide.25

Only the exo-epoxide is genotoxic because the SN2 reaction between the epoxide
and DNA requires the guanyl N7 atom attack from the back side of the molecule

13
(Scheme 2.3).26 The exo-epoxide reacts with DNA leading to >98% yield with Kd = 1.4
mM for binding/dissociation and kcat = 35 s-1 for a rate constant yielding product.27

Scheme 2.3Kinetics of AFB1 exo-8,9-epoxide interaction with DNA
(Johnson, et. al., 1997)

Figure 2.1 Intercalation ofAFB1 into DNA (Smela et. al., 2001)
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2.2 Cytochrome P450s

Since the toxic AFB1 exo-8,9-epoxide metabolite is formed from AFB1 by
cytochrome P450 (CYP450), we first reviewed the function of CYP450 anddecided to
investigate whether cis-terpenones have the potential to block the activity of CYP450.
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Scheme 2.4 Aflatoxin B1 oxidation products (Guengerich, et. al., 1998)

The cytochrome P450s (CYP450) are a series of enzymes, which are very
important in human and animal’s biological cell function. CYP450s have been a focus for
more than three decades in biochemistry, toxicology and pharmacology because of their
unique enzyme catalysis properties.28 These properties are associated with their unique
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folded structures.29-30 Until now, no other molecules have been found to have the same
folding as CYP450. Thus, the actions and properties of CYP450, such as activation of
molecular oxygen, binding of redox partners and the stereochemistry must be based on
their structures.

Figure 2.2 Human CYP450 3A4, [1TQN, Homo sapiens] ribbon detail. Color key: helix
structures, gray; strand structures, blue; PERF consensus, green; K-helix concensus,
purple; heme-binding consensus, orange; heme ligand, yellow.
(http://www.p450.kvl.dk/gallery/CYP3A4.jpg based on the work for the following paper:
Paquette SM, Bak S, Feyereisen R. DNA and Cell Biology (2000) 19 (5):307-17)

In the 1950s, Hayaishi first suggested activation and transfer of molecular oxygen
by an iron-containing enzyme.31This discovery changed the traditional view that the
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oxygen in biological molecules is from water exclusively. A subsequent study revealed
the mechanisms of molecular oxygen activation and transfer catalyzed by CYP450s and
novel iron redox chemistry.

The major reactions catalyzed by CYP450 are alkane hydroxylation.32 For
example, the most common reaction is that an organic substrate is oxidized by insertion
of oxygen.
RH + O2 + 2H+ + 2e- → ROH + H2O

The mechanism is shown as Scheme 2.5:

Scheme 2.5 Consensus catalytic cycle for oxygen activation and transfer by cytochrome
P45028
1) Substrate binds to enzyme to form an enzyme-substrate adduct.
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2) One electron can be transferred from NAD(P)H via electron transfer chain,
reducing the ferric iron to the ferrous iron.
3) Molecular oxygen binds to ferrous heme to form P450-dioxygen complex.
4) Another one-electron reduction and protonation occurs to form Fe(III)hydroperoxy complex.
5) The above complex is protonated and one water molecule is released to from ironoxo intermediate.
6) ROH is released as final product.

Scheme 2.6 Possible pathway for oxygen-atom transfer from the active ferryl species to
form the alcohol28
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CYP450 can oxidize saturated hydrocarbons, even as stable as cyclohexane. Not
like reactions performed by chromates and permanganate, the hydroxylations catalyzed
by iron-containing enzymes occur selectively under mild conditions. This property
attracted many researchers’ attention. The possible mechanism is shown in the above
scheme 2.6. The caged radical and ion pair may be formed during rearrangement.

Much of the interest in CYP450 research has focused on human CYP450s.
CYP450s are the major enzymes that metabolize drugs, thus, it is extremely important to
study human CYP450s in the pharmaceutical industry. Since the first human P450 was
identified and purified in the late 1970s, all 57 human P450 genes have been
identified.28,33-35 CYP450s have been found in many tissues, such as liver, lung, kidney
and brain. Most of them exist in the endoplasmic reticulum (microsomal CYP450s); only
6 out of 57 are located in mitochondria.28

19

Figure 2.3 Contribution of major human P450s to the Phase I metabolism of all drugs
currently marketed42

The study of individual human CYP450s demonstrated that three major CYP450s
(3A4, 2D6, 2C9) account for ~75 % of drug metabolism, and 90~95 % of all drug
metabolism can be performed by 6~7 CYP450s (Figure 2.3).36 CYP450s also metabolize
chemical carcinogens, but this metabolism usually involves CYP 1A1, 1B1, 2A6, and
2E1 instead of 2C19 and 2D6.37

2.3 Chemoprevention compounds against AFB1

Several chemoprevention compounds have been developed against AFB1-induced
cytotoxicity and carcinogenic activity, such as oltipraz and chlorophyllins.38-41Oltipraz
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can inhibit the phase one CYP450 enzyme and meanwhile induce phase two glutathione
S-transferases (GSTs), which permit the formation of AFB1-glutathione conjugates, thus,
preventing the formation of AFB1-DNA complex (Scheme 2.7). But the drawbacks of
oltipraz are that it may cause acute gastrointestinal toxicity and induce estrogen
responsive genes.

Scheme 2.7 Effect of oltipraz on the metabolism of aflatoxin B139
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Chlorophyllin is another compound, which is in clinic trial. It diminishes the
bioactivity of AFB1 by forming a complex with it, but its low complex constant and high
water solubility lead to a high dose requirement and low effectiveness. Moreover, more
mechanistic studies are required for chlorophyllin.

Most chemoprevention compounds focus on phase two enzymes to induce the
formation of the AFB1-glutathione complex, while Chlorophyllin can form a complex
with AFB1 by itself. Although there are several effective P450 inhibitors, there are few
reported in the chemoprevention against AFB1. These findings suggest that new
chemoprevention compounds against AFB1 induced cell cytotoxicity are needed.
Therefore, our goal was to search for new chemoprevention compounds that may inhibit
the phase one CYP450 enzyme to block the formation of AFB1 epoxide.

22

Chapter 3
Chemoprotective Actions of Hydroxy-Cis-Terpenone (HCT)
Against Aflatoxin

3.1 Actions of HCT on liver cell viability

The cis-terpenone HCT and its analogs (Scheme 3.1) have been designed and
synthesized in Dr. Zhou’s lab. As mentioned above, Dr. Zhou predicted that the cisterpenones would be hydroxylated and oxidized in liver cells, and the predicted
metabolite that resembles resveratrol, would inhibit cytochrome P450 activity. If this
hypothesis is correct, we would expect the metabolites to block the conversion of AFB1
to AFB1 exo-8,9-epoxide and therefore, protect cells. As a first step in testing this
hypothesis, we examined the effects of cis-terpenones on the viability of HepG2 cells
exposed to AFB1.

H
RO

O

R= Me; H; Ac
Scheme 3.1 Structure of cis-terpenone analogs
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Methods:

All chemicals were purchased from Fisher Scientific (Pittsburgh,PA) or SigmaAldrich (Milwaukee, WI) and used without furtherpurification. NMR spectra of the
synthesized compounds wereobtained by Variant NMR spectrometers. Electrospray
ionizationmass spectroscopy (ESI-MS) analysis was carried out with Q-TOF2from
Micromass (Manchester, U.K.).

2-(3-Methoxybenzyl)-2-(2,6-dimethylhepta-1,5-dienyl)-1,3-dithiane (5). To a
solution of thiol-protected citral as a 1:1 cis/trans mixture (1.10 g, 4.54 mmol) in dry THF
(20 mL) at -40 °C(acetonitrile/dry ice bath) was slowly added a solution of 1.05 equivof
n-BuLi (1.6 M in hexanes, 2.84 mL) under N2. The resultingreaction solution was stirred
at -40 °C for 1 h, and then a solutionof 3-methoxybenzyl chloride (650 mg, 4.16 mmol)
in dry THF (10mL) was added. The reaction mixture was maintained at -40 °Cfor 8 h and
then slowly warmed to room temperature over 16 hunder N2. The reaction solution was
quenched with brine (100 mL)and extracted with ether (100 mL X 2). The organic layers
werecollected, dried with MgSO4, and concentrated. A flash columnseparation (0-2%
EtOAc in hexanes) afforded the desired productas a cis/trans diastereoisomeric mixture
(0.60 g) in 40% yield.Further separation of the isomers was not carried out because
thesubsequent cyclization step afforded diastereoisomerically pure ciscompounds.1H
NMR (CDCl3, 300 MHz) for the cis/trans diastereomericmixture: δ7.23-7.14 (m, 1H),
6.95-6.72 (m, 3H), 5.40(s, 1H), 5.19-5.05 (m, 1H), 3.83-3.76 (m, 3H), 3.37-3.25 (m,2H),
3.00-2.74 (m, 4H), 2.54-2.44 (m, 1H), 2.17-1.90 (m, 5H),1.84-1.52 (m, 9H). 13C NMR
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(CDCl3, 75 MHz) observed: δ 159.1,143.2, 142.5, 137.8, 137.5, 132.0, 128.8, 128.7,
127.9, 127.4, 124.5,124.3, 123.7, 117.0, 116.9, 112.5, 112.4, 55.3, 54.4, 47.0, 46.8,41.8,
32.8, 28.2, 28.0, 26.9, 26.4, 26.0, 25.6, 24.7, 18.0, 17.9, 17.3.ESI-MS calcd for
C21H31OS2 (M - H+), 361.17; found, 361.07.

1-(3-Methoxyphenyl)-4,8-dimethylnona-3,7-dienyl-2-one (6).To a solution of 5
(300 mg, 0.83 mmol) in MeOH/H2O (9:1, 25mL) was added 1.1 equiv of HgO and
HgCl2. The resulting reactionsolution was stirred at room temperature for 4 h. The
reactionsolution was diluted with CH2Cl2, and the precipitation was filteredthrough a 5
μm Acrodisc filter. The solution was washed with brine,dried with MgSO4, and
concentrated. The desired product waspurified by a flash column separation (0-10%
EtOAc in hexanes)as a cis/trans diastereomeric mixture (160 mg) in 71% yield. 1HNMR
(CDCl3, 300 MHz) for the cis/trans diastereomeric mixture:δ 7.24-7.14 (m, 1H), 6.846.74 (m, 2H), 6.09 (s, 1H), 5.05-4.98 (m, 1H), 3.79 (s, 3H), 3.74-3.67 (m, 2H), 2.18-2.09
(m,7H), 1.17-1.56 (m, 6H). 13C NMR (CDCl3, 75 MHz) observed:δ 198.1, 160.3, 160.0,
136.7, 132.7, 129.7, 129.5, 123.2, 123.1,122.6, 122.1, 121.9, 119.7, 115.3, 115.2, 114.1,
113.0, 112.5, 64.1,55.5, 55.3, 51.7, 46.7, 41.5, 34.2, 26.9, 26.3, 26.0, 25.9, 19.7,
17.9.ESI-MS calcd for C18H25O2 (M + H+), 273.19; found, 273.07.

4b,5,6,7,8,8a-cis-Hexahydro-2-methoxy-4b,8,8-trimethylphenanthren9(10H)-one (1).To a solution of 6 (130 mg, 0.48 mmol) indry CH3NO2 (10 mL) at room
temperature was added 10 equiv ofBF3•Et2O, and the resulting reaction solution was
stirred under N2for 2 h. The reaction solution was diluted with saturated NaHCO3(150
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mL) and extracted with CH2Cl2 (150 mL X 3). The organiclayers were collected, dried
with MgSO4, and concentrated. Thedesired compound was purified by a flash column
separation (0-5% EtOAc in hexanes) as a diastereoisomeric pure oil (50 mg) in38% yield.
1

H NMR (CDCl3, 300 MHz): δ 7.23 (d, J )8.7 Hz,1H), 6.80 (dd, J1 ) 8.7 Hz, J2 ) 2.7 Hz,

1H), 6.61 (d, J ) 2.7 Hz,1H), 3.80 (s, 3H), 3.69 (d, J ) 22.8 Hz, 1H), 3.48 (d, J ) 22.8
Hz,1H), 2.48 (d, J ) 14.1 Hz, 1H), 2.10 (s, 1H), 1.54-1.46 (m, 2H),1.34-1.23 (m, 3H),
1.05 (s, 3H), 0.95 (s, 3H), 0.34 (s, 3H). 13CNMR (CDCl3, 75 MHz): δ 212.5, 158.2,
135.6, 134.0, 125.2, 113.9,112.7, 66.7, 55.4, 44.4, 42.4, 38.3, 36.4, 34.4, 33.8, 32.4, 22.7,
19.0.ESI-MS calcd for C18H25O2 (M + H+), 273.19; found, 273.12.

4b,5,6,7,8,8a-cis-Hexahydro-2-hydroxy-4b,8,8-trimethylphenanthren-9(10H)one (2).To a solution of 1 (15 mg, 0.05 mmol) inCH2Cl2 (2.0 mL) under N2 was added a
solution of BBr3 (1.0 M inheptane, 1.0 mL). The resulting solution was stirred at
roomtemperature for 2 h. The reaction solution was quenched with brine(100 mL) and
extracted with EtOAc (100 mL _ 2). The organiclayers were collected, dried with
MgSO4, and concentrated. A flashcolumn separation (5-35% EtOAc in hexanes) afforded
the desiredproduct (8 mg) as an oil in 57% yield. 1H NMR (CDCl3, 300MHz): δ 7.18 (d, J
)8.7 Hz, 1H), 6.73 (dd, J1 ) 8.7 Hz, J2 ) 2.4Hz, 1H), 6.57 (d, J ) 2.4 Hz, 1H), 4.78 (bs,
1H), 3.67 (d, J ) 22.8Hz, 1H), 3.45 (d, J ) 22.8 Hz, 1H), 2.48 (d, J ) 12.3 Hz, 1H),2.10 (s,
1H), 1.56-1.47 (m, 2H), 1.35-1.23 (m, 3H), 1.05 (s, 3H),0.95 (s, 3H), 0.35 (s, 3H). 13C
NMR (CDCl3, 75 MHz): δ 212.6,154.1, 135.9, 134.0, 125.4, 115.3, 114.2, 66.7, 44.2,
42.4 38.3, 36.4,34.4, 33.8, 32.4, 22.7, 19.0. ESI-MS calcd for C17H21O2 (M - H+),257.15;
found, 257.33.
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4b,5,6,7,8,8a-cis-Hexahydro-2-acetyloxy-4b,8,8-trimethylphenanthren9(10H)-one (3). To a solution of 2 (5 mg, 0.02 mmol)in CH3CN (2.0 mL) was added
solutions of Ac2O and Et3N (1.0M, 1.0 mL each). The resulting solution was stirred at
roomtemperature for 4 h. The reaction solution was extracted with Et2O(50 mL X 2). The
organic layers were collected, dried with MgSO4,and concentrated. A flash column
separation (5-20% EtOAc inhexanes) afforded the desired product (5 mg) as an oil in
84% yield.1H NMR (CDCl3, 300 MHz): δ 7.33 (d, J )8.7 Hz, 1H), 6.99(dd, J1 ) 8.7 Hz, J2
) 2.4 Hz, 1H), 6.83 (d, J ) 2.4 Hz, 1H), 3.71(d, J ) 22.8 Hz, 1H), 3.50 (d, J ) 22.8 Hz, 1H),
2.50 (d, J ) 14.1Hz, 1H), 2.29 (s, 3H), 2.12 (s, 1H), 1.56-1.48 (m, 2H), 1.37-1.23 (m, 3H),
1.07 (s, 3H), 0.95 (s, 3H), 0.33 (s, 3H). 13C NMR(CDCl3, 75 MHz): δ 211.7, 169.7,
149.2, 139.3, 135.8, 125.2,121.5, 120.3, 66.5, 44.2, 42.3, 38.7, 36.4, 34.5, 33.5, 32.3,
22.7,21.4, 18.9. ESI-MS calcd for C19H23O3 (M - H+), 299.16; found,299.33.
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Scheme 3.2 Synthesis of cis-Terpenones 1-3

Detailed mechanism is showed in Scheme 3.3.
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Scheme 3.3Detailed synthesis mechanism of cis-Terpenones

30
Cells: Human HepG2 cells were obtained from ATCC (Manassas, VA) and
maintained in 75 cm2 flasks in the incubator at 37 °C with 5 % CO2. The growth medium
contained 90 % Minimum Essential Eagle medium (MEM) from Invitrogen (Carlsbad,
CA) and 10 % heat-inactivated fetal bovine serum (FBS) plus 2 mM L-glutamine, 0.75
g/L sodium bicarbonate, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 50
Unit/mL penicillin, and 50 μg/mL streptomycin.

MTT cell viability

MTT Assay

The MTT assay is a common colorimetric method used in the laboratory to test
mitochondrial reductase activity of living cells. [MTT = (3-(4,5-Dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide, a tetrazole)] Since mitochondrial reductase of dead
cells cannot function properly, the MTT assay is also used to measure the viability of
cells.

Scheme 3.4 MTT Reduction
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The yellow color MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, a tetrazole) is reduced to the purple color formazan in the presence of
mitochondrial reductase. By measuring the absorbance at different wavelength (570nm
and 670nm), cell viability can be determined quantitatively.

The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
solution was prepared at 5 mg/mL in PBS solution (pH 7.4), filtered, and stored at 4 °C.
The MTT lysis buffer was prepared by dissolving 25 g of SDS in 100 mL of 50 % DMF
in water, and the pH was adjusted to 4.7 with a solution of 2.5 % HCl in 80 % acetic acid.
HepG2 cells were seeded in a 96-well cell cultured plate at 30,000 cells per well and
maintained in 200 μL ofgrowth medium at 37o C for 4 hours prior to treatment with
AFB1 and cis-terpenone compounds. Treatment included medium only, 2 μM AFB1
only, 2 μM AFB1 plus 10, 20, 40 μM cis-terpenone and 40 μM cis-terpenone only. The
final DMSO concentration was kept at 0.15 %. After 72 hours incubation, 10 μL stock
MTT solution was added to each well and incubated overnight. After incubation, the
medium solution was removed and 100μL MTT lysis buffer was added. After 10 hours,
the absorbance of each well at 570 nm (background correction at 690 nm) was obtained
with an íQuant plate reader (BioTek Instruments, VT).
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Measurement of CYP 1A/B activity with the EROD assay:

EROD Assay

N

O

O

7-ethoxyresorufin

CYP 1A
O

HO

N

O

O

resorufin

Scheme 3.57-ethoxyresorufin deethylation reaction

The ethoxyresorufin-O-deethylase (EROD) assay is widely used in bio labs to
measure the amount of CYP 1A enzyme. 7-ethoxyresorufin acts as a substrate for CYP
1A and can undergo deethylation to form the product resorufin. The catalytic activity of
this reaction indicates the present amount of CYP 1A. By measuring the florescence of
resorufin, EROD assay provides a fast and direct method to detect CYP 1A enzyme.
Dicumarol was added to the reaction to inhibit reductase activity.

HepG2 cells were seeded at 50,000 cells/well in a 96-well plate. After plating for
4 h, various treatments included DMSO only, TCDD only, TCDD plus cis-terpenones 13, and cis-terpenones only. The final concentration of TCDD was 1 nM, and the
concentrations of cis-terpenones 1-3 were 0.1, 1, 10, and 20 μM. The final volume of
each well was 200 μL containing 0.1 % DMSO. After 24 h, the EROD assay was
performed. Briefly, fresh medium (175 μL per well) containing 2% serum, 8 μM 7-
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ethoxyresorufin, and 10 μM dicumarol were added to each well and then incubated for 1
h..The resulting medium (150 μL each) was transferred to a 96-well black plate, and
ethanol (150 μL/well) was added. The fluorescence intensity of each well between 580
and 600 nm was obtained by a Cary Eclipse fluorescence spectrometer (Varian
Instruments, CA) with an exciting wavelength at 550 nm. The fluorescent intensity at 590
nm (λmax) was used as the index for EROD activity, and statistical analyses (one-way
ANOVA with Dunnett’s test) were performed with GraphPad Prism software. All of the
experiments were independently repeated at least three times. Also, the cell viability
MTT assay was carried out in a manner similar to that described above.
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Results and discussion:
As to confirm the stereochemistry of our cis-terpenone compounds, one of the
compounds was performed 2D NOESY NMR spectrum.

Figure 3.12D NOESY NMR Spectrum of cis-terpenone compound
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Clearly, figure 3.2 shows no cytotoxicity when cells were treated with a high
concentration (40 μM) of cis-terponones for 72 hours.
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O
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Figure3.2 Chemo-protection with cis-terpenones against AFB1-induced cytotoxicity.
HepG2 cells were co-treated with AFB1 (2 μM) and cisterpenones 1-3 at various
concentrations (10-40 μM) and incubated for 72 h. The percentage of viable cells was
based on cells treated with medium only. Each bar represents the mean ±SD of four
replicates. The data are representative of three independent experiments. *P < 0.05 and
**P < 0.001 compared to treatment with AFB1 by one way ANOVA and Dunnett’s test.
Second, we treated cells with AFB1 at 2 μM and co-treated with AFB1 and
different cis-terpenones at various concentrations (10-40 μM). From the above Figure, we
can clearly see that 2μM AFB1 caused 50 % cell death. When cis-terpenones were
combined with AFB1 in HepG2 cells, increasing cell viability was observed (up to 80 %
at 40 μM). This suggests that our cis-terpenone compounds may be potential
chemoprevention compounds against AFB1.
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3.2 Actions of Cis-Terpenones on Cytochrome P450 (CYP450)
In the previous AFB1 inhibition studies, we showed that cis-terpenones had
promising chemoprevention effects on AFB1-induced cell cytotoxicity. Our next project
was to reveal the mechanism of cis-terpenones inhibition of AFB1. Since the toxic AFB1
exo-8,9-epoxide metabolite is formed from AFB1 by cytochrome P450 (CYP450), we
decided to investigate whether cis-terpenones block the activity of CYP450.

In order to examine the inhibition mechanism of our cis-terpenone compounds,
we first investigated effects of the cis terpenones on induction of CYP1A/B activity in
HepG2 cells. The family-1 of CYP450 is induced in many cells by carcinogens and other
compounds, and is of great research interest due to its involvement in cancer
development. CYP family-1 includes CYP 1A1, 1A2, and 1B1. Both CYP 1A1 and 1B1
are known to activate a large variety of chemical carcinogens that result in cell damage
and initiation of tumor development.42-44 For example, both benzo[a]pyrene and
aflatoxin B1 are converted by CYP 1A1 and 1B1 to reactive metabolites resulting in
DNA damage.45,46 Since the actual CYP1A/B amount in HepG2 cells is undetectable,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was used to induce CYP1A/B activity.47
Indeed, as described below, we found that cis-terpenone compounds at 10 μM can inhibit
TCDD-induced CYP1A/B activity by 50 % compared to control.
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Figure 3.3Inhibition of TCDD-induced P450 1A/B activity with cis-terpenones.HepG2
cells were co-treated with TCDD (1 nM) and cis-terpenones 1, 2 or 3 and incubated for24
h. The activity of P450 1A/B was determined with the EROD assay. Bars represent the
mean ± SD of EROD activity at 590 nm in 4 replicates. The data are representative of
three independent experiments. C: Vehicle (0.1 % DMSO) only. * P<0.05, ** P<0.001
compared to TCDD only with one way ANOVA and Dunnett's test.
We found that cis-terpenones can effectively inhibit TCDD-induced P450 1A/B
activity in HepG2 cells as shown in Figure 3.3. Without TCDD treatment, P450 1A/B
activity is very low, whereas TCDD (1 nM) significantly induced P450 1A/B activity.
When co-treated with cis-terpenones and TCDD, P450 1A/B enzymatic activity
decreased with increasing concentrations of cis-terpenones. Cis-terpenones 1-3 at 10 μM
reduced theinduced 1A/B activity by approximately 50%. In addition, no cytotoxicity in
HepG2 cells under these conditions was observed. These results implied that cisterpenones 1-3 could be used as chemopreventive agents that inhibit the activity of P450
1A/B and thereby protect cells against AFB1 induced cytotoxicity. The inhibitory effect
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with cis-terpenones may be due to either the inhibition of enzyme activity or the
suppression of the expression level of the enzyme. Therefore, further study of the
inhibitory mechanism with cis-terpenones 1-3was undertaken.

3.3 Liver Microsomes and P450 3A4 Studies with HCT

Dr. Zhou used HPLC to investigate effects of hydroxy-cis-terpenone on the
activation and conversion of AFB1 by purified human CYP450 3A4in the presence and
absence of human liver microsomes, which have high CYP450 3A4 activity.33,34Effects
of both HCT and oxidized HCT (OHCT) were investigated because Dr. Zhou determined
that HCT is converted to OHCT in aqueous media at pH 7.4, the normal pH of human
plasma.

a. phosphate buffer, pH 7.4
or b. buffer pH 7.4 and Cu2+

H
O

HO

or c. CH2Cl2, Et3N, and Cu2+

H
O

HO
O

HCT

HO
H+

O O

OHCT

H
O
H

H
O

HO
HO

O H

HO
HO

Scheme 3.6 OHCT as the Spontaneous Oxidation Product of HCT50

O

H
O
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Effects of cis-terpenones were compared with those of ketoconazole, a well
known inhibitor of CYP450s, cholesterol as a structural analogue of HCT, and αnaphthoflavone, which is able to change the metabolite profile of AFB1 metabolism with
P450 3A4 by enhancing the production of exo-AFB1-epoxide and reducing that of
aflatoxin Q1.48

To assist with this study, I used the MTT assay to compare the cytotoxicity of
ketoconazole, HCT and oxidized HCT on HepG2 cells. The cytotoxicity of benzopyrene
on HepG2 cells was also tested by me.

Dr. Zhou found that 1µM ketoconazole inhibited the P450 3A4 activity in isolated
human liver microsomes (Sigma) to the same extent as 40 µM HCT and OHCT, that is
the metabolite product of HCT (Fig. 3.4 and Fig. 3.5).50Although 20 µM ketoconazole
had the same effect as 40 µM OHCT against cell cytotoxicity induced by 2 µM AFB1
(Fig 3.6), this concentration of ketoconazole caused 20% cell death while HCT and
OHCT exhibited no cytotoxicity, even at 60 µM. This implied that HCT and OHCT were
less toxic than ketoconazole when they were used to treat live cells, therefore, HCT and
OHCT may be used as an alternative compound instead of ketoconazole.

In addition, cholesterol was included as the structural control in the study because
cholesterol has a similar carbon skeleton as that of HCT. However, no inhibitory effect
was observed with cholesterol up to 100 µM, which indicated that the inhibitory effect of
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HCT on the metabolic conversion of AFB1 was unique to the functional groups and
stereochemistry of HCT.

The results of the above experiments implied that that both HCT and OHCT block
the conversion of AFB1 to AFB1-epoxide by CYP450 3A4.

Fig 3.4 Inhibitory effects of HCT on the activity of purified P450 3A450
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Fig 3.5 Inhibitory effects of OHCT on the activity of purified P450 3A450
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Fig 3.6Chemo-protection with OHCT and ketoconazole against AFB1-induced
cytotoxicity. HepG2 cells were co-treated with AFB1 (2 μM) and OHCT and
ketoconazole at various concentrations (10-60 μM) and incubated for 72 h. The
percentage of viable cells was based on cells treated with medium only. Each bar
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represents the mean ±SD of four replicates. The data are representative of three
independent experiments. *P < 0.05 and **P < 0.001 compared to treatment with AFB1
by one way ANOVA and Dunnett’s test.
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Chapter 4
Actions of HCT on AFB1 Accumulation
in HepG2 Cells

In the previous chapters, we demonstrated that novel cis-terpenones synthesized
in our laboratory protect HepG2 cells against AFB1-induced cell death (up to 80 % at 40
µM) for 72 hours.49 Additionally, based on our CYP450 enzymes studies, we observed
that these molecules reduce Phase I activation of AFB1 by CYP450 enzymes.50 In order
to further investigate the inhibitory mechanism of cis-terpenones, the following study was
designed to determine whether cis-terpenones influence the uptake of AFB1 into HepG2
cellsand secondarily to determine whether specific transporter proteins influence AFB1
accumulation in these cells.

4.1 Cellular Uptake and Efflux of AFB1

AFB1 is taken up by liver cells and metabolized to AFB1 epoxide-glutathione
conjugates51-55which are excreted from cells by the multi-drug resistant protein-1
(MRP1),53 an important efflux transporter in many cells.56 MRP1 also transports
unmodified AFB1, but the transport rate is low compared to that of conjugated AFB1
metabolites.53 Chi and Devlin observed saturable uptake of AFB1 by rat hepatocytes,55
but Müller and Petzinger reported that uptake of radiolabeled AFB1 in rat hepatocytes
occurs primarily by non-ionic diffusion through the lipid membrane and is not saturated
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by unlabeled AFB1.53 No transport mechanism for AFB1 has been identified in human
cells except for MRP1.

Methods:

Reagents:3H-labeled AFB1 ([3H]-AFB1, 29.2 Ci/mole) was obtained from
Moravek Biochemicals (Brea, CA). 3H-labeled estrone sulfate ([3H]-ES, 53-55 Ci/mole)
was obtained from Perkin-Elmer). Unless specifically indicated, all other chemicals were
purchased from Fisher Scientific (Pittsburg, PA) or Sigma-Aldrich (Saint Louis, MO) and
used without further purification. Hydroxy- cis-terpenone (HCT) was synthesized as
previously reported.13Stock solutions of unlabeled AFB1 and HCT, carbamyl cyanide 4(trifluoromethoxy) phenylhydrazone (FCCP), and omeprazole were prepared in dimethyl
sulfoxide (DMSO) and stored at −20 oC. Estrone-3-sulfate potassium salt was dissolved
in DMSO, and stock solutions of 17-β-estradiol, corticosterone, nigericin sodium salt,
and verapamil were prepared fresh in ethanol prior to dilution in uptake buffer (described
below). Stocks of 17-β-estradiol glucuronide were prepared in 0.1 M KOH and stored at
-20 oC. Probenecid was dissolved in uptake buffer, and the pH was adjusted to 7.4 with
KOH prior to use. Stocks of para-amino-hippuric acid, desipramine,glutathione (GSH),
gluthione ester (GSHE), N-ethyl maleimide (NEM), and diothiothrietol (DTT)were
prepared in deionized water and stored at −20 oC. Final concentrations of DMSO or
ethanol in cell assays were kept below 0.2%.
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Cells: Human HepG2 cells were obtained from ATCC (Manassas, VA) and
maintained in 75 cm2 flasks in the incubator at 37 °C with 5 % CO2. The growth medium
contained 90 % Minimum Essential Eagle medium (MEM) from Invitrogen (Carlsbad,
CA) and 10 % heat-inactivated fetal bovine serum (FBS) plus 2 mM L-glutamine, 0.75
g/L sodium bicarbonate, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 50
Unit/mL penicillin, and 50 μg/mL streptomycin.

Chinese hamster ovarian cells (CHO cells) transfected with the human OATPB
gene and wild type (WT) CHO cells were obtained from Dr. Bruno Stieger, University of
Zürich, Switzerland. The CHO cells were maintained in DMEM 12320332 (Invitrogen)
supplemented with 50 Unit/mL penicillin and 50 μg/mL streptomycin, 10 % heatinactivated FBS, and 50 mg/L proline. The medium for the cells transfected with
OATPB also contained geneticin G-418 (500 mg/L) to select for the neomycin resistance
of the transfected cells.

Transport assay:

Cells were seeded in a 24 well plate at 106 cells / well and maintained in 1 mL
ofgrowth medium at 37o C in the incubator for 16 h prior to the transport assay. For the
assay, the plate was removed from the incubator and kept at room temperature for 20 min
to equilibrate. Cells were washed twice with 1 ml of sucrose/Hepes (SH) buffer,which
contained 0.32 M sucroseand 10 mM Hepes adjusted to pH 7.4 with KOH. The final SH
wash was removed at 1.5 min intervals, and cells were incubated for the times indicated
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at room temperature in 0.8 ml of uptake buffercontaining radiolabeled substrate 15 nM
[3H]-AFB1 (or where indicated [3H]-estrone sulfate ([3H]-ES), and inhibitors or
competitive substrates or vehicle. For most assays the uptake buffer was that used by
Finn et al for sodium-independent vesicular transport57 (SH supplemented with 4 mM
MgSO4 and 4 mM KCl). In selected assays the transport buffer contained SH
supplemented with 140 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM
glucose. Transport was stopped by removing the uptake buffer and washing twice with
SH. After the wash, cells were lysed for 5 min in 0.8 mL of 0.2 MNaOH containing 1 %
sodium dodecyl sulfate. To measure cellular accumulation of radioactivity, a 200 µL
aliquot of each cell lysate was added to 5 mL of Scinti-Safe Plus-50% (Fisher Scientific,
Fair Lawn, New Jersey), and counted in the LS6000 IC scintillation counter
(Beckman/Coulter). A 200 µL aliquot of uptake buffer also was counted to verify the
total amount of radioactivity added to cells. For determination of background
radioactivity, cells incubated for zero time after addition of [3H]-labeled substratein
uptake buffer were included in each assay. Background radioactivity was subtracted
from all measurements of cellular radioactivity.

Binding Assay:

Human liver microsomes were purchased from Sigma (S2442). Each assay tube
contained 0.1 μg of microsomal protein and 15 nM [3H]-AFB1 or 15 nM [3H]-estrone
sulfate ([3H]-ES) and inhibitors or vehicle as indicated in a total volume of 200 μl of
uptake buffer as described for the transport assay. All incubations were conducted at 29
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°C for the times indicated. The reaction was terminated by addition of 1.5 ml cold SH
buffer and rapid filtration through 0.2 μm Supor 200 membranes (Pall/Gelman # 60300)
in a Millipore sampling manifold. The reaction tubes were washed three times with 1.0
ml of SH buffer, which was transferred to the filter and rapidly filtered as above. Filters
were transferred to 5 mL of Scinti-Safe Plus-50% (Fisher Scientific), and radioactivity
was measured with a Beckman LS6000IC scintillation counter.

Data Analyses: Data were analyzed with Prism version 4.00 (GraphPad Software
Inc., San Diego, CA). All assays were repeated at least three times independently.
Percentage values were transformed to arcsin and compared with the appropriate control
by an unpaired t test or by analysis of variance (ANOVA) with Dunnet’s post hoc test.

4.2 Results and Discussion:
As seen in Figure 4.1, [3H]-AFB1accumulation reached a maximum by 30 min,
and 40 µM HCT inhibited [3H]-AFB1accumulationby approximately 50 % at every time
point.
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Figure4.1Time-dependent accumulation of [3H]-AFB1 by HepG2 cells.Cells were
incubated with sodium-free uptake buffer containing 15 nM [3H]-AFB1 + vehicle (V) or
[3H]-AFB1 + 40 μM hydroxyl-cis-terpenone (HCT) for the times indicated. Cells were
washed, lysed, and radioactivity was measured in 25% of the lysate. Background
radioactivity measured at zero time was subtracted from each measurement. Points
represent means ± S.E. of at least 3 replicates obtained in separate experiments.
As shown in Figure 4.2, HCT inhibition of [3H]-AFB1 accumulation was
concentration dependent, and the maximum was approximately 60 % at 60 µM.
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Figure 4.2Concentration dependent inhibition of [3H]-AFB1 accumulation with
HCT.Accumulation in HepG2 cells was measured at 10 min as described in Figure4.1.
(IC50 = 4µM)
The co-treatment with unlabeled AFB1 decreased cellular accumulation of [3H]AFB1 as seen in Figure 4.3. These initial results suggestedeither saturation of a
specifictransport mechanism or saturation of AFB1 binding to internal cellular
components, such as proteins. Inhibition of efflux would be expected to increase cellular
accumulation of
[3H]-AFB1.
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Figure 4.3 Concentration dependent inhibition of [3H]-AFB1 accumulation with
AFB1.Accumulation of [3H]-AFB1in HepG2 cells was measured at 10 min as described
in Figure 4.1. (IC50 = 2.4 µM)
To investigatethe ATP-dependence of AFB1 accumulation in HepG2 cells, the
mitochondrial ATPase inhibitor sodium azide, which blocks activity of MRP1 and many
other ATP-dependent transporters, was added to cells with or without HCT. No effect on
accumulation of [3H]-AFB1 was observed in the presence of sodium azide in sodium-free
and glucose-free buffer (Figure 4.4). Furthermore, no effects were observed when the
experiment was repeated with a buffer containing sodium and glucose or with the
ATPase inhibitor sodium orthovanadate (Na3VO4) at 1 mM (data not shown). These
findings support the idea that HCT modulates an accumulation mechanism that is not
ATP-dependent; however, others have reported that sub-lethal concentrations of NaN3 do
not completely block the high ATPase activity in HepG2 cells.58 As indicated below,
other methods were thenused to determine whether specific transporters affect the
accumulation of AFB1 in HepG2 cells.

[3H] AFB1 Accumulation
(% Control)
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Figure 4.4 Effects of 3 mM sodium azide (NaN3) on [3H]-AFB1 accumulation.
Accumulation of [3H]-AFB1wasmeasured at 10 min in HepG2 cells treated with vehicle
(V) or hydroxyl-cis-terpenone at 40 µM (HCT). Bars represent mean ± S.E. of at least 3
replicates. * P < 0.01.
To investigateuptakemechanisms for AFB1, buffer substitutions and several
inhibitors or competitive substratesof organic cation transporters (OCT), organic anion
transporters (OAT/OATP), andmulti-drug-resistant efflux transporters were screened,
because many of these transporters are expressed in Hep G2 cells58 – 69and transport
neutral lipophilic molecules, such as AFB1. Concentrations were determined either by
limits of solubility or the maximal range of concentration used by previous investigators
to inhibit transport activity. Initial results of this screen are shown in Figure 4.5, and a
follow-up of these experiments is shown in Fig. 4.6.
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Figure 4.5 Effects of maximal concentrations of inhibitors and substrates on [3H]AFB1 accumulation in HepG2 cells. Accumulation of [3H]-AFB1in HepG2 cells was
measured at 10 min as described in Figure 4.1. Bars represent the mean ± S.E. of 3-4
replicates. * P < 0.05; P < 0.01 compared to the appropriate vehicle for each treatment.
Concentrations: Control, vehicles only; 60 μM AFB1, 60 μM hydroxy cis-terpenone
(HCT), 500 μM probenecid, 500 μM verapamil, 200 μM 17-β-estradiol (17-β-E), 200
μM 17-β-estradiol glucuronide (17-β-EG), 5 mM glutathione ethyl ester (GSHE), 5 mM
glutathione (GSH), 80 μM estrone-3-sulfate (E-3-S), 50 μM corticosterone (CORT), 1
mM para-amino-hippuric acid (PAH), 50 μM desipramine (DESIP), 4 mM NaCl, 1 μM
reserpine, 5 μM carbamyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), 100
μM omeprazole.
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Figure 4.6 Effects of ions andN-ethylmaleimide on [3H]-AFB1 accumulation in
HepG2 cells.Accumulation of [3H]-AFB1in HepG2 cells was measured at 10 min as
described in Figure4.1. Bars represent the mean ± S.E. of 3-4 replicates. * P < 0.05; P <
0.01 compared to the appropriate vehicle for each treatment. Control – Average of
vehicles in each experiment. Concentrations: 4 mM KBr substituted for KCl in the
uptake buffer, 500 μM N-ethylmaleimide (NEM), 500 μM dithiothrietol (DTT), 1 μM
nigericin (NIG), and 10 μM Valinomycin (Val) -all in uptake buffer.
Because greater than 50 % inhibition of [3H]-AFB1 accumulation was observed
with verapamil, probenecid, and 17-β-estradiol, additional assays were performed to
determine the concentration-dependence of the inhibition (Figure 4.7, 4.8, and 4.9).
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Figure4.7 Inhibition of [3H]-AFB1 accumulation with probenecid in HepG2 cells.
Accumulation of [3H]-AFB1in HepG2 cells was measured at 10 min as described in
Figure4.1(IC50 = 30µM)
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Figure4.8 Inhibition of [3H]-AFB1 accumulation with verapamil in HepG2 cells.
Accumulation of [3H]-AFB1in HepG2 cells was measured at 10 min as described in
Figure4.1(IC50 = 100µM)
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Figure 4.9 Inhibition of [3H]-AFB1 accumulation with 17-β-Estradiol in HepG2
cells. Accumulation of [3H]-AFB1in HepG2 cells was measured at 10 min as described in
Figure 4.1.(IC50 = 30µM).
Accumulation assays initially were performed with the sodium-free uptake buffer,
and substitution of 4 mM NaCl for 4 mM KCl did not affect [3H]-AFB1 transport (Fig.
4.5). Substitution of a transport buffer containing 140 mM NaCl also had no apparent
affect on accumulation of [3H]-AFB1 (data not shown). Reserpine, which inhibits both
vesicular transporters and most MDR efflux transporters,68 had no effect on accumulation
of [3H]-AFB1 (Fig. 4.5). These results suggested AFB1 accumulation in Hep G2 cells is
not dependent on sodium, vesicular transporters, or most transporters in the MDR
transporter family, at least under the conditions of the assay.

Verapamil inhibits organic cation uptake transporters OCT 1, 2 and 3 and the
multi-drug resistant efflux transporter MDR1 (also known as p-glycoprotein). Although
HepG2 cells express MDR1,62,65-68 inhibition of this efflux transporter would be expected
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to increase accumulation of substrates. Failure of verapamil to increase accumulation of
[3H]-AFB1 was consistent with absence of reserpine effects on accumulation (Fig. 4.5)
suggesting MDR1 was not involved in AFB1 transport. Inhibition of [3H]-AFB1 by
verapamil(Fig. 4.5 and 4.8) suggested OCTs may be involved in AFB1 transport, but the
OCT inhibitor desipramine showed no effect on [3H]-AFB1 accumulation (Figure 4.5).
These findings suggested verapamil blocked accumulation of [3H]-AFB1 by another
mechanism, and we then investigated whether verapamil inhibits binding of [3H]-AFB1
to intracellular proteins.

As described in Chapter 3, AFB1 is activated by CYPs in liver microsomes.
Binding of AFB1 to microsomal enzymes could account for saturable accumulation in
cells. We tested the hypothesis that unlabeled AFB1 and other lipophilic molecules, such
as HCT and verapamil, inhibit binding of [3H]-AFB1 to liver microsomal proteins. As
illustrated in Figure 4.10, verapamil, HCT and unlabeled AFB1 (at concentrations used to
inhibit cellular accumulation of [3H]-AFB1) inhibit binding of of [3H]-AFB1 within 30
sec to human liver microsomal proteins. Binding did not increase when incubation
continued for 10 min. Additional binding assays demonstrated that 17-β-estradiol
inhibited binding of [3H]-AFB1 to human liver microsomal protein, but probenecid,
FCCP, omeprazole (OME) and corticosterone had no significant effect on binding of
[3H]-AFB1 to liver microsomal proteins (Figure 4.11).
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Figure 4.10HCT, verapamil and unlabeled AFB1 decreased binding of [3H]-AFB1 to
liver microsomes. Human liver microsomes (0.1 μg protein) were incubated for 30 sec at
ambient temperature with [3H]-AFB1 + Vehicle (VEH), HCT (40 μM), VER (verapamil,
100 μM) or unlabeled AFB1 (10 μM). All treatments differ from vehicle  P < 0.01.
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Figure 4.11 17-β-estradiol binding of [3H]-AFB1 to human liver microsomes. Human
livermicrosomes (0.1 μg protein) were incubated for 10 min at ambient temperature with
[3H]-AFB1 + Vehicle (V), probenecid (Prob), FCCP, corticosterone (Cort), omeprazole
(Ome) or 17-β-estradiol (Estradiol). P < 0.01.
These findings suggested inhibition of binding to intracellular microsomal
proteins accounts for most of the inhibitory effects of HCT, AFB1, and verapamil on
accumulation of [3H]-AFB1 in HepG2 cells. Absence of effects of probenecid, carbamyl
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and omeprazole (OME) on
binding of [3H]-AFB1 to microsomes suggested additional mechanisms modulate
accumulation of [3H]-AFB1 in HepG2 cells.

AFB1 transport by MRP-1, which is known to excrete AFB1 from cells, is
enhanced by the presence of glutathione.53 A small decrease in accumulation of [3H]AFB1 (Fig. 4.5) in the presence of a glutathione ester (GSHE)that penetrates cells was
consistent with GSH-stimulation of MRP-1 mediated efflux of AFB1 conjugates.53
Inhibition of [3H]-AFB1 accumulation by 17-β-EG and estrone sulfate (substrates of
several OATs, OATPs, MDR1 and MRP efflux transporters)was consistent with
inhibition of the OAT/ OATP uptake transporters56,69and not consistent with inhibition of
efflux.Similarly, probenecid inhibits MRP1, OATs and some OATPs, inhibition of [3H]AFB1 accumulation was consistent with OAT or OATP-mediated uptake. These findings
left open the possibility that OATs or OATPs influence AFB1 uptake and suggested
thatMRP1 has little effect on AFB1 transport in cultured Hep G2 cells in the absence of
GSH supplements.
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Inhibition with the H+ ionophore, carbamyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP), which also uncouples mitochondrial oxidative
phosphorylation, suggested dependence of AFB1 accumulation on membrane potential
and/or pH. Failure of 100 µM KCl, valinomycin + KCl, or nigericin to alter [3H]-AFB1
accumulation (Fig. 4.6) suggested that changes in membrane potential did not alter AFB1
accumulation in HepG2 cells. These findings suggested the major action of FCCP on
accumulation was due to its action on H+. Inhibition of accumulation with omeprazole,
an inhibitor of H+ ATPase (H+ pumps) further suggested that H+ gradients influence
accumulation of [3H]-AFB1.

Inhibition of [3H]-AFB1accumulation by the sulfhydryl alkylating agent Nethylmaleimide (NEM) and reversal by dithiothrietol (DTT) suggested sulfhydryls are
important for accumulation (Figure 4.6). Substitution of KBr for KCl decreased
accumulation of [3H]-AFB1 and suggested chloride ions affect AFB1 accumulation.
Although inhibition of [3H]-AFB1 accumulation with probenecid suggested an
OAT or OATP may be involved in the uptake of AFB1 in HepG2 cells, failure of PAH to
inhibit AFB1 transport (Figure 4.5) eliminated most OATs and suggested OATPs, such
as OATPB (also, known as OATP2B1), may take up AFB1. Gene expression of OATPs
have been detected previously by others in HepG2 cells,58,65and OATPB is an H+ coupled
transporter.70 Furthermore, OATPB activity is modulated by several steroids.71Based on
evidence that extracellular acid increases OATPB activity in intestinal cells,69 we
examined effects of changes in pH of the HepG2 cell medium. In contrast to the
stimulatory effects of acid on OATPB activity,Figure 4.12 indicated that extracellular
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acid reduced [3H]-AFB1 accumulation in these cells.This was our first evidence against
OATPB-mediated transport of [3H]-AFB1.

Figure 4.12 Effects of pH on accumulation of [3H]-AFB1 in Hep G2
cells.Accumulation of [3H]-AFB1in HepG2 cells was measured at 10 min as described in
Figure4.1. Bars represent the mean ± S.E. of 3-4 replicates. ;* P < 0.05 compared
accumulation at pH 7.35.
To clarify whether OATPB affects AFB1, the accumulation of [3H]-AFB1 was
measured in Chinese hamster ovarian cells (CHO cells) transfected with the OATPB
gene. Estrone sulfate is a common substrate of OATPB, and accumulation of [3H]-ES in
these cells was measured as a positive control. As demonstrated in Figure 4.13, CHO
cells expressing OATPB accumulated approximately two fold more [3H]-estrone sulfate
([3H]-ES) than wild type cells without the gene; however, no accumulation of [3H]-AFB1
above background levels was detected in either the wild type cells or cells expressing
OATPB incubated in uptake buffer or a transport buffer typically used for OAPB (data
not shown). A high concentration of HCT (100 µM) inhibited accumulation of [3H]-ES
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by approximately 15 % in both wild type and transfected cells (Figure 4.14), suggesting
no specific effects of HCT on OATPB-mediated transport.

Figure 4.13Accumulation of [3H]-ES in wild type (WT) CHO cellsand CHO cells
expressing OATPB. Accumulation of [3H]-estrone sulfate (ES) was measured after 10
min incubation. *P < 0.01
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Figure 4.14 Effects of HCT on accumulation of [3H]-ES in wild type (WT) CHO
cellsand CHO cells expressing OATPB. Accumulation of [3H]-estrone sulfate (ES) was
measured after 10 min incubation with vehicle or as 100 µM HCT as described in Figure
4.1.*P < 0.05
In summary, these findings indicate AFB1 accumulation in HepG2 cells is
saturable and suggest binding to intracellular proteins has an important effect on the rapid
accumulation of AFB1 in these cells. Inhibition of AFB1 accumulation with GSHE and
glucuronide is consistent with effects of the efflux transporter MRP1 on efflux of AFB1
conjugates reported by others.53 The data also suggest one or more unidentified transport
mechanism(s) that are proton dependent may influence accumulation of AFB1 in these
cells.
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Chapter 5
Preliminary Studies of Other biologicalactions of HCTand
OHCT
5.1 Anti-inflammatory Effects of HCT on Macrophages
When we investigated the interaction between HCT and AFB1, we were also
interested in other biological actions of HCT. Based on evidence that terpenes modulate
immune cell production of cytokines,74we examined effects of HCT on production of
interleukin-6 (IL-6), and tumor necrosis factor α (TNFα) by macrophages. Macrophages
produce these cytokines and exhibit biological activity when the cells are activated by
external invasion or chemical mediators, such as the bacterial endotoxin,
lipopolysaccharide (LPS).75

TNFα and IL-6 both are responsible for pro-inflammatory actions against
infection; for example, they lead to an increase of body temperature and promote
production of other pro-inflammatory cytokines,76, 77, 78 butIL-6 also has antiinflammatory actions, such as suppression of TNF α expression.77, 79TNF includes a
family of cytokines causing cell death, but TNFα is also one of the most potent cytokines
promoting inflammation.

64

Figure 5.1 Image of human Interleukin-6
(http://upload.wikimedia.org/wikipedia/commons/e/e7/IL6_Crystal_Structure.rsh.png,
based on original data from Somers, et. al., 1997)80
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Figure 5.2 Image of human TNFα
(http://upload.wikimedia.org/wikipedia/commons/3/3b/TNFa_Crystal_Structure.rsh.png,
based on original data from Eck, et. al., 1989)81

Methods:
RAW 264.7 Macrophage Cell Line
Murine macrophages from the RAW264.7 cell line (ATTC, Rockville, MD) were
cultured in RPMI (Invitrogen) supplemented with 10% heat inactivated fetal bovine
serum, 1% L-glutamine, 1% non-essential amino acids, 1% minimal essential medium
vitamins, 100 units/ml penicillin and 100 μg/ml streptomycin. Cell cultures were
maintained at 37 °C in 5 % CO2 in 75 cm2 tissue culture flasks (Costar Brand, Fisher
Scientific, Suwanee, GA). The cultures were sub-cultured twice weekly.
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Effects of HCT on LPS- induced production of cytokines
RAW264.7 macrophages (0.75 x 106) were added to each well of a 24-well tissue
culture plate and incubated for 24 hrs at 37 ºC in 5 % CO2 to allow for macrophage
adherence. The RAWS264.7 cells doubled within 24 hours; therefore, the final
concentration of all macrophages was (1.5 x 106)cells per well. The cells were washed
twice with warm (37 ºC) phosphate buffered saline (PBS), pH 7.4, then incubated for
either 4 or 24 hrs in 500 μl of serum-free RPMI 1640 medium with and without LPS
(Lipopolysaccharide, fromE. coli – serotype 055:B5, Sigma, St. Louis, MO) and HCT or
vehicle at concentrations indicated in the figure legends. Extracellular fluid was removed
and centrifuged at 500 x g for 10 minutes at 4 ºC to remove cellular debris, and the
supernatant was frozen at -20 ºC until assayed for IL-6 and TNFα. The remaining
macrophage monolayer within each well was washed once with RPMI 1640 and twice
with PBS. All PBS was removed, and the monolayer was lysed for subsequent
measurement of total cellular protein. The cell monolayer was lysed with 150 μl of ice
cold buffer containing 0.05 M Tris (pH 7.5), 0.3 M NaCl, 2 mM EDTA, 1.0 % Triton-X
100, 2 μg/ml leupeptin, 1 μg/ml aprotinin and 0.2 mM phenylmethylsulfonylfluoride.
Protein concentrations of the lysates were determined with the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, CA) and read at 590 nm in the μQuant Universal
Microplate reader purchased from Bio-Tek Instruments (Winooski, VT).
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Measurement of cytokines
Extracellular IL-6 and TNFα concentrations were assayed with the OptEIA Multi
Component ELISA Set for either Mouse IL-6 or Mouse TNFα from BD Biosciences,
(San Diego, CA). The assays were performed in accordance with the manufacturer’s
instructions. The plates were read at 450 and 570 nm with a μQuant Universal Microplate
Spectrophotometer. Concentrations were calculated with the manufacturer’s KC4
software.

Data Analyses
Analysis of variance (ANOVA) and the Neuman-Keuls test were used to compare
effects of LPS and LPS + HCT or vehicle on macrophage production of TNFα and IL-6.
The analyses were performed with Prism software (Graphpad, San Diego, CA).
Differences were considered statistically significant at P < 0.05.

Results and Discussion

As shown in Fig 5.3, the amount of IL-6 and TNFα in RAW264.7 cells was
increased by treatment with LPScompared to treatment with media alone. LPS acted as
an endotoxin and caused a strong cell immune response, thus, leading to a significant
increase of TNFα within 4 h and an increase in IL-6 within 24 h after LPS. When cells
were co-treated with LPS and HCT, at 10, 20 and 40 μM, the HCT caused a decrease of
approximately 60 % IL-6 and TNFα compared to LPS only.
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Figure 5.3 Effects of HCT on LPS-stimulated release of IL-6 and TNFα by
RAW264.7 cells. Macrophages were incubated for 4 h for measurement of TNFα or for
24 h for measurement of IL-6 with media or LPS (30 ng/ml), or LPS + vehicle
(V=DMSO) or the concentration of HCT shown. * P < 0.01 ** P < 0.001 compared to
LPS + V.
As shown in Fig 5.4, the amount of TNFα produced by RAW264.7 cells
continued to be elevated 24 h after treatment with LPS; however, the inhibitory response
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to HCT was greater at 10 μM than at 20 and 40 μM. This may be because the higher
concentrations of HCT significantly decreased IL-6, which is known to inhibit TNFα
expression.77The lower IL-6may have permitted a small increase in TNFα at 24 h, despite
the inhibitory effects of HCT, and suggests that effects of cytokines, such as IL-6, may
over-ride effects of HCT.

Figure 5.4 Effects of HCT on LPS-stimulated release of TNFα by RAW264.7 cells.
Macrophages were incubated for 24 h with media (C) or LPS (30 ng/ml) or LPS + vehicle
(V=DMSO) or LPS + the concentration of HCT shown. * P < 0.01 ** P < 0.001
compared to LPS + V
This result indicates that μM concentrations of HCT may have an impact on LPSstimulated IL-6 and TNFα. No effects of HCT on macrophage total cellular protein were
observed (data not shown).

5.2 Biological Actions of OHCT
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As described in Chapter 3, Dr. Zhou demonstrated that HCT is oxidized to OHCT
in aqueous media and that both OHCT and HCT inhibit CYP P450- 3A4. Furthermore,
he demonstrated that OHCT is stable in aqueous buffer for at least 72 h as determined by
HPLC, and I demonstrated that OHCT exhibits no cytotoxicity at concentrations as high
60 μM as determined by the MTT assay.50

While these studies were in progress, Dr. Ghislaine Mayer (Department of
Biology, Virginia Commonwealth University) in collaboration with Dr. Stewart and Dr.
Zhou discovered that OHCT effectively kills Plasmodium falciparum, a parasite that
causes human malaria.82 They found that OHCT inhibited in vitro survival of all blood
stages of P. falciparum clones, including gametocytes that are transmitted by mosquitoes
and clones that are resistant to the anti-malarial drugs chloroquine and artemisinin83. As
shown in Table 5.1, OHCT with an IC50< 40 nM was significantly more effective than
chloroquine against gametocytes (Table 5.1).

Scheme 5.1Structure of Chloroquine

Table 5.1. OHCT (nM) inhibits growth of P. falciparum gametocytes*
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OHCT

Chloroquine

OHCT

Chloroquine

(Stage I and II)

(Stage I and II)

(Stage III and IV)

(Stage III and
IV)

(IC50)

22 ± 3.4

394 ± 127.0

36 ± 9.0

944 ± 92.0

(IC90)

174 ± 5.4

1520 ± 27.5

226 ± 49.3

2109 ± 85.2

*IC50 and IC90 values (nM) represent the mean ± SE of duplicate experiments, each
performed in duplicate (vehicle and 8 concentrations per experiment). Stages of pure
gametocyte cultures of the P. falciparum Dd2Nm clone were counted microscopically in
7,000 – 10,000 erythrocytes (from Mayer et al., 2009).
The protective effects of OHCT and HCT against AFB1 and the anti-malarial
actions of OHCT suggested these molecules are potential new drug candidates. Cellular
transport molecules are important in both uptake and removal of drugs from cells and
change the bioavailability and half-life of the drugs in animals or human patients.84,85If
OHCT and HCT influence transporter activity and are administered to patients taking
other drugs, the bioavailability of the drugs could be altered. Therefore, I began
preliminary studiesto examine effects of OHCT on transporter function.

To investigate effects of OHCT on activity of two of the major efflux transporter
in liver cells (MRP1 and MDR1), we used radiolabeled estrone sulfate, which is a general
substrate for these transporters and for organic anion transporters (OATs) and organic
anion transporting polypeptides (OATPs).
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Scheme 5.2Structure of Estrone 3-sulfate potassium salt

5.3 Effects of OHCT on Cellular MDR1-mediated Efflux of AFB1 and Estrone
Sulfate

As mentioned previously, inhibitory effects of HCT on AFB1 accumulation in
HepG2 cells theoreticallycould be explained by stimulation of an efflux transporter.
HepG2 cells express high levels of the efflux transporter MDR1. Although this
transporter has little effect on efflux of conjugated AFB1 metabolites53, it is not known if
it transports unconjugated AFB1. In order to investigate the effect of OHCT on MDR1
transporter activity, we obtained MES-SA/DX5 cells over-expressing MDR1 from ATCC
and studied the interactive effects of HCT and MDR1 inhibitors on accumulation of both
AFB1 and the transporter substrate estrone sulfate.

Methods:

Cells: MES-SA/DX5 cells were obtained from ATCC (Manassas, VA) and
maintained in 75 cm2 flasks in the incubator at 37 °C with 5 % CO2. The growth medium
contained 90 % McCoy’s 5a Medium Modified from ATCC (Manassas, VA) and 10 %

73
heat-inactivated fetal bovine serum (FBS) plus 50 Unit/mL penicillin, and 50 μg/mL
streptomycin.

Transport assay: Cells were seeded in a 24 well plate at 106 cells / well and
maintained in 1 mL ofgrowth medium at 37o C in the incubator for 16 h prior to the
transport assay. For the assay, the plate was removed from the incubator and kept at
room temperature for 20 min to equilibrate. Cells were washed twice with 1 ml of
sucrose/Hepes (SH) buffer which contained 0.32 M sucroseand 10 mM Hepes and
adjusted to pH 7.4 with KOH. The final SH wash was removed at 1.5 min intervals, and
cells were incubated for the times indicated at room temperature in 0.8 ml of uptake
buffer, which containedSH supplemented with 4 mM MgSO4, 4 mM KCl, 15 nM [3H]AFB1, and inhibitors/substrates or vehicles. The cellular uptake was stopped by
removing the uptake buffer and washing twice with SH. After the wash, cells were lysed
for 5 min in 0.8 mL of 0.2 M NaOH containing 1 % sodium dodecyl sulfate. To measure
cellular accumulation of radioactivity, a 400 µL aliquot of each cell lysate was added to 5
mL of Scinti-Safe Plus-50% (Fisher Scientific) and counted in the LS6000 IC
scintillation counter (Beckman/Coulter). A 400 µL aliquot of uptake buffer also was
counted to verify the total amount of radioactivity added to cells. For determination of
background radioactivity, cells incubated for zero time in uptake buffer were included in
each assay. Background radioactivity was subtracted from all measurements of cellular
radioactivity.
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Data Analyses: Data were analyzed with Prism version 4.00 (GraphPad Software
Inc., San Diego, CA). All assays were repeated at least three times independently.
Percentage values were transformed to arcsin and compared with the appropriate control
by an unpaired t test.
Results and Discussion:
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Figure 5.5 Effects of OHCT on [3H]-AFB1 accumulation. Accumulation of [3H]AFB1wasmeasured at 10 min in MES-SA/DX5 cells treated with vehicle (V) or OHCT at
10, 20, 40 µM and verapamil at 100 µM. Bars represent mean ± S.E. of at least 3
replicates.
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Figure 5.6 Effects of OHCT on [3H]-ES accumulation. Accumulation of [3H]ESwasmeasured at 10 min in MES-SA/DX5 cells treated with vehicle (V) or OHCT at
0.1, 80, 100, or 120µM and verapamil at 100 µM. Bars represent mean ± S.E. of at least
3 replicates.
As seen in Figure 5.5, neither OHCT nor 100 µM verapamil had any effect on
cellular accumulation of [3H]-AFB1, implying that AFB1 was not transported by MDR1.
In order to verify MDR1 expression of MES-SA/DX5 cells and the inhibition of
verapamil on MDR1, radiolabeled estrone sulfate, which is a general substrate for MDR1
transporter, was used. In Figure 5.6, it is clearly shown that 100 µM verapamil inhibited
MDR1 transporter and caused approximately 50 % increase of cellular accumulation of
[3H]-ES.OHCT at a high concentration (120 µM)appeared to stimulate MDR1-mediated
efflux. Additional study is needed to verify this finding.
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5.4 Preliminary studies with H69AR cells expressing MRP1

Near the end of this project, I began optimizing conditions for maintaining cells
that express the efflux transporter, MRP1.

Methods:

Cells: H69AR cells were obtained from ATCC (Manassas, VA) and maintained
in 75 cm2 flasks in the incubator at 37 °C with 5 % CO2. The growth medium contained
80 % RPMI-1640 from Invitrogen (Carlsbad, CA) and 20 % heat-inactivated fetal bovine
serum (FBS) plus 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500
mg/L glucose, and 1500 mg/L sodium bicarbonate, 50 Unit/mL penicillin, and 50 μg/mL
streptomycin.

Transport assay: In a 24 well plate, 50 μL L-poly-lysine (0.1 g/L) was added to
each well to promote adherence of the cells to the wells. After 5 minutes, L-poly-lysine
solution was removed and was thoroughly rinsed with sterile tissue culture grade water.
The plate was then allowed to dry two hours before seeding. Cells were seeded at 0.5x106
cells / well and maintained in 1 mL ofgrowth medium at 37o C in the incubator for 16 h
prior to the transport assay. For the assay, the plate was removed from the incubator and
kept at room temperature for 20 min to equilibrate. The medium was removed at 1.5 min
intervals, and cells were incubated for the times indicated at room temperature in 0.8 ml
of uptake buffer, which containedSH supplemented with 4 mM MgSO4, 4 mM KCl, 15
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nM [3H]-AFB1, and inhibitors/substrates or vehicles. The cellular uptake was stopped by
removing the uptake buffer and washing once with SH. After the wash, cells were lysed
for 5 min in 0.8 mL of 0.2 M NaOH containing 1 % sodium dodecyl sulfate. To measure
cellular accumulation of radioactivity, a 400 µL aliquot of each cell lysate was added to 5
mL of Scinti-Safe Plus-50% (Fisher Scientific) and counted in the LS6000 IC
scintillation counter (Beckman/Coulter). A 400 µL aliquot of uptake buffer also was
counted to verify the total amount of radioactivity added to cells. For determination of
background radioactivity, cells incubated for zero time in uptake buffer were included in
each assay. Background radioactivity was subtracted from all measurements of cellular
radioactivity.

Data Analyses: Data were analyzed with Prism version 4.00 (GraphPad Software
Inc., San Diego, CA). All assays were repeated at least three times independently.
Percentage values were transformed to arcsin and compared with the appropriate control
by an unpaired t test.
Results and Discussion:

No accumulation of [3H]-ES could be detected in the absence of an inhibitor of
MRP1-mediated efflux. As shown in Figure 5.7, accumulation of [3H]-ES reached a
maximum by 5 min. In future studies GSHE will be added to estrone sulfate to optimize
efflux, and effects of OHCT on efflux will be investigated. Because of the difficulty of
maintaining cells that express MRP1, I was not able to continue these studies. Further
investigation will be needed to determine actions of OHCT on MRPs.
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Figure. 5.7 Time-dependent accumulation of [3H]-ES by H69AR cells in the
presence of the MRP1 inhibitor MK571. Cells were incubated with uptake buffer
containing 15 nM [3H]-ES + 50 μM MK571 for the times indicated.
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